Cited by 619Alzheimer's disease research and treatmentsAdvanced Glycation End Products researchNeuroinflammation and Neurodegeneration Mechanisms

A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease

Open access
Deane, Rashid, Singh, Itender, Sagare, Abhay P., Bell, Robert D., Ross, Nathan T., LaRue, Barbra, Love, Rachal, Perry, Sheldon +8 more·2012·Journal of Clinical Investigation

Abstract

In Alzheimer disease (AD), amyloid β peptide (Aβ) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates Aβ-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked Aβ binding to the V domain of RAGE and inhibited Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APPsw/0 mice overexpressing human Aβ-precursor protein, a transgenic mouse model of AD with established Aβ pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating Aβ40 and Aβ42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited β-secretase activity and Aβ production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced Aβ40 and Aβ42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APPsw/0 mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of Aβ-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci58642

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • RAGE-mediated reentry or influx of circulating Aβ across the blood-brain barrier is associated with neuroinflammatory response, cerebral blood flow reductions, and blood-brain barrier breakdown.

    “which is associated with neuroinflammatory response, CBF reductions, and BBB breakdown (134, 136)”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [136]

    The Discussion (page unavailable) describes RAGE-mediated entry of circulating Aβ across the BBB. The Results and Discussion also link RAGE inhibition in the mouse model with improved cerebral blood-flow responses and reduced neuroinflammation. But the Introduction (page unavailable) describes BBB breakdown as a possible contributor to peripheral Aβ influx, not as an effect associated with RAGE-mediated influx; the claim's BBB-breakdown link is therefore unsupported. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Blocking RAGE at the BBB reduces Aβ reentry into the brain, inhibits neuroinflammation, and improves CBF in a mouse model of AD.

    “On the other hand, blocking RAGE at the BBB (134) effectively reduces A 𝛃 reentry into the brain, inhibits neuroinflammation, and improves CBF in a mouse model of AD (134, 136).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [136]

    The Results report that blocking RAGE at the BBB inhibited Aβ influx into the brain, while FPS-ZM1 restored cerebral blood-flow responses in aged APPsw/0 mice. The Discussion attributes suppression of neuroinflammation to FPS-ZM1’s actions in the brain as well as at the BBB; the BBB-only blocker was only marginally effective for blood flow. Thus the claim overstates what BBB blockade alone achieved. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Under pathological conditions, RAGE mediates reentry or influx of circulating Aβ across the blood-brain barrier into the brain.

    “Under pathological conditions, RAGE mediates reentry or influx of circulating A 𝛃 across the BBB into the brain, which is associated with neuroinflammatory response, CBF reductions, and BBB breakdown (134, 136)”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [136]

  • Increased RAGE expression likely contributes to circulating amyloid-beta influx, neuroinflammation, and reduced cerebral blood flow in Alzheimer's disease.

    “likely contributing to circulating A 𝛃 influx, neuroinflammation, and reduced CBF (134, 136).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [136]

  • The three RAGE forms bind various ligands with similar affinities, including AGEs and amyloid β peptide.

    “The three RAGE forms bind various ligands with similar affinities, including multiple advanced glycation end-products (AGEs) and amyloid β peptide31–37.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., Thiyagarajan, M., Zarcone, T., Fritz, G., Friedman, A. E., Miller, B. L., & Zlokovic, B. V.
Affiliations
University of Rochester Medicine (US)
Venue
Journal of Clinical Investigation
Published
2012-04-02
Volume
122
Issue
4
Pages
1377-1392
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2079815081
Cited by
619
References
66
Citations by year
2026: 27 · 2025: 42 · 2024: 42 · 2023: 46 · 2022: 52 · 2021: 54 · 2020: 64 · 2019: 34 · 2018: 43 · 2017: 46 · 2016: 43 · 2015: 43 · 2014: 29 · 2013: 36 · 2012: 17
FWCI
27.24
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Drug Discovery Foundation
  • National Institutes of Health
  • National Institute on Aging (R37AG023084, AG029481, R01AG029481)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta, receptor for advanced glycation end products, RAGE inhibitors, FPS-ZM1, blood-brain barrier, microglial activation, neuroinflammation, beta-secretase inhibition, cognitive impairment, cerebral blood flow, disease-modifying therapy
MeSH terms
Receptor for Advanced Glycation End Products, Aging, Alzheimer Disease, Animals, Benzamides, Blood-Brain Barrier, Brain, Cerebrovascular Circulation, Cricetulus, Disease Models, Animal, Drug Evaluation, Preclinical, Cricetinae, Humans, Male, Mice, Transgenic, Peptide Fragments, Psychomotor Performance, Receptors, Immunologic, Recombinant Fusion Proteins, Amyloid beta-Peptides, CHO Cells, Neuroprotective Agents, Mice, Amyloid Precursor Protein Secretases, Small Molecule Libraries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review